Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment Source: Breathe, 17 (2) 210024; 10.1183/20734735.0024-2021 Year: 2021
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019
Two therapy option in patients with uncontrolled asthma Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018
A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019
Life-sustaining treatment preferences of patients with severe COPD Source: Annual Congress 2010 - Pulmonary rehabilitation and chronic care: new developments in interventions, assessment and care Year: 2010
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015
The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001
Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020
Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019
Real-world treatment patterns of benralizumab therapy for patients with severe asthma Source: Virtual Congress 2020 – Diagnosis and management of asthma Year: 2020
Are current treatment protocols adequate for children with mild intermittent asthma? Source: Eur Respir J 2005; 26: Suppl. 49, 397s Year: 2005
Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
The way to improve the steroid sensitivity of target cells of patients with severe therapy resistant asthma Source: Eur Respir J 2006; 28: Suppl. 50, 313s Year: 2006
Macrolide therapy in asthma: limited treatment, long-term improvement Source: Eur Respir J 2009; 33: 1239 Year: 2009